Anti-MLL N-Terminus Monoclonal Antibody
Catalog no.: 34041
Size: 100ug Protein G-purified antibody in PBS, pH 7.4.
MLL (Mixed Lineage Leukemia) is a proto- oncogene that is mutated in a variety of acute leukemias. MLL is proteolytically processed into 2 fragments, MLLN and MLLC, that display opposite transcriptional properties. Processed MLLN and MLLC associate with each other via N-terminal and C-terminal intramolecular interaction domains. MLL processing occurs rapidly after translation and is followed by phosphorylation of MLLC. MLLN displays transcriptional repression activity, whereas MLLC has strong transcriptional activation properties. Leukemia-associated MLL fusion proteins lack the MLL processing sites, do not undergo cleavage, and are unable to interact with MLLC. These observations suggest that posttranslational modifications of MLL may be involved in regulating MLL activity as a transcription factor, and this aspect of its function is perturbed by leukemogenic fusions.
Antigen: Maltose-binding fusion protein containing MLL amino acids 161-356 (Uniprot #Q03164).
Clone no.: N4.4
Host: Mouse Antibody
Preservatives: None – available on request.
This antibody recognizes human and mouse MLLN.
Immunoblotting: use at 2ug/ml. A band of ~300kDa is detected.
Immunoprecipitation: use 2-10ug per 500ul (1-3mg/ml) of cell lysate.
Positive control: K562 cell lysate.
These are recommended concentrations. Endusers should determine optimal concentrations for their applications.
Dilute in PBS or medium that is identical to that used in the assay system.
STORAGE AND STABILITY
This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.
Yokoyama A et al. 2002 Blood 100: 3710-3718.
Yokoyama A et al. 2005 Cell 123: 207-218.
For in vitro investigational use only. Not intended for diagnostic or therapeutic applications.